Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT01371994
First received: June 10, 2011
Last updated: October 6, 2014
Last verified: October 2014

June 10, 2011
October 6, 2014
August 2011
October 2013   (final data collection date for primary outcome measure)
Time From First Dose to Urinary Continence [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Urinary continence is defined as the first of three consecutive 24-hour days in which a participant uses no pads, or a pad for security which remains completely dry, during the 12-week treatment period. Participants recorded their daily pad usage in an electronic diary. Kaplan-Meier curves were used to estimate the distribution of cumulative incidence of urinary continence over the 12-week study treatment period. Participants who did not experience the event during the 12-week treatment period were considered as censored at the End of Treatment (EOT) visit or Week 12, whichever occurs first.
The time from the date of first dose to the date of urinary continence [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Urinary continence will be defined as the first of three consecutive 24 hour days which subject uses 0 pads, or a pad for security which remains completely dry, during the 12 week study
Complete list of historical versions of study NCT01371994 on ClinicalTrials.gov Archive Site
  • Percentage of Participants Who Gain Continence During 12-week Treatment Period [ Time Frame: Weeks 4, 8, and 12 ] [ Designated as safety issue: No ]

    Urinary continence is defined as three consecutive 24-hour days in which a participant uses no pads or a pad for security which remains completely dry. Participants recorded their daily pad usage in an electronic diary during the 12-week treatment period.

    End of treatment is the last on-treatment assessment during the treatment period.

  • Average Daily Pad Usage at Baseline [ Time Frame: Baseline (7 days prior to Day 1) ] [ Designated as safety issue: No ]
    Participants recorded their daily pad usage in an electronic diary during the 12-week treatment period. A 7-day window was used to calculate the average daily pad usage.
  • Change From Baseline in Average Daily Pad Usage [ Time Frame: Baseline and Weeks 4, 8 and 12 ] [ Designated as safety issue: No ]

    Participants recorded their daily pad usage in an electronic diary during the 12-week treatment period. A 7-day window was used to calculate the average daily pad usage.

    End of treatment is the last on-treatment assessment during the treatment period.

  • American Urology Association Symptom Score (AUASS) at Baseline [ Time Frame: Baseline ] [ Designated as safety issue: No ]

    Quality of life was measured by the American Urology Association Symptom Score (AUASS). The AUASS includes 7 questions addressing symptoms of frequency, urgency, nocturia (waking during the night to urinate), hesitancy, weak urinary, incomplete emptying, and intermittence. The questionnaire asked participants to consider how these symptoms affected them over the past month on a scale from 0 (not at all) to 5 (almost always).

    The AUASS is a sum of the 7 symptom scores and ranges from 0 (best) to 35 (worst).

  • Change From Baseline in American Urology Association Symptom Score (AUASS) [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]

    Quality of life was measured by the American Urology Association Symptom Score (AUASS). The AUASS includes 7 questions addressing symptoms of frequency, urgency, nocturia (waking during the night to urinate), hesitancy, weak urinary, incomplete emptying, and intermittence. The questionnaire asked participants to consider how these symptoms affected them over the past month on a scale from 0 (not at all) to 5 (almost always).

    The AUASS Symptom Score is a sum of the 7 symptom scores and ranges from 0 (best) to 35 (worst).

    End of treatment is the last on-treatment assessment during the treatment period.

  • American Urology Association Quality of Life (QOL) Score at Baseline [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    The American Urology Association (AUA) includes a single bother question which asked participants how they would feel if they had to live with their urinary condition the way it is now for the rest of their life. The bother question score ranges from 0 (delighted) to 6 (terrible).
  • Change From Baseline in American Urology Association Quality of Life (QOL) Score [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]

    The American Urology Association (AUA) includes a single bother question which asked participants how they would feel if they had to live with their urinary condition the way it is now for the rest of their life. The bother question score ranges from 0 (delighted) to 6 (terrible).

    End of treatment is the last on-treatment assessment during the treatment period.

  • International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) QOL Score at Baseline [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    The ICIQ-SF is a validated self-administered questionnaire designed for patients with urinary incontinence. The ICIQ-SF assessed urinary incontinence using 3 scored questions which ask patients about their frequency of urine leakage, how much urine leakage, and perceived impact of leakage on daily lives over the past 4 weeks. The ICIQ-SF is a sum of the 3 scores and ranges from 0 (low bother) to 21 (maximum bother).
  • Change From Baseline in International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) QOL Score [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    The ICIQ-SF is a validated self-administered questionnaire designed for patients with urinary incontinence. The ICIQ-SF assessed urinary incontinence using 3 scored questions which ask patients about their frequency of urine leakage, how much urine leakage, and perceived impact of leakage on daily lives over the past 4 weeks. The ICIQ-SF is a sum of the 3 scores and ranges from 0 (low bother) to 21 (maximum bother).
  • Baseline Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent work time missed is derived from the number of hours of work missed due to urinary leakage as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed.
  • Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent work time missed is derived from the number of hours of work missed due to urinary leakage as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed. A negative change from Baseline indicates improvement.
  • Baseline Work Productivity and Activity Impairment (WPAI): Percent Impairment While Working [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent impairment while working was derived from the participant's assessment of the degree to which urinary leakage affected their productivity while working. A higher percentage indicates greater impairment and less productivity.
  • Change From Baseline in Work Productivity Assessment Index (WPAI): Percent Impairment While Working [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent impairment while working was derived from the participant's assessment of the degree to which urinary leakage affected their productivity while working. A higher percentage indicates greater impairment and less productivity. A negative change from Baseline indicates improvement.
  • Baseline Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent overall work impairment takes into account both hours missed due to urinary leakage and the participant's assessment of the degree to which urinary leakage affected their productivity while working. A higher percentage indicates greater impairment and less productivity.
  • Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Overall Work Impairment [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent overall work impairment takes into account both hours missed due to urinary leakage and the participant's assessment of the degree to which urinary leakage affected their productivity while working. A higher percentage indicates greater impairment and less productivity. A negative change from Baseline indicates improvement.
  • Baseline Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent activity impairment is derived from the participant's assessment of the degree to which their urinary leakage affected their regular daily activities. A higher percentage indicates greater impairment and less productivity.
  • Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Activity Impairment [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    Work productivity was measured by the Work Productivity and Activity Impairment Questionnaire (WPAI). WPAI asks participants about the effect of urinary leakage on their ability to perform their work-related functions and carry out daily activities over the past seven days. Percent activity impairment is derived from the participant's assessment of the degree to which their urinary leakage affected their regular daily activities. A higher percentage indicates greater impairment and less productivity. A negative change from Baseline indicates improvement.
  • Time From Baseline to First Day of Returning to Work [ Time Frame: From Baseline to Week 12 ] [ Designated as safety issue: No ]
    The time from Baseline to first day of returning to work was estimated using the Kaplan-Meier method.
  • Proportion of subjects who gain urinary continence [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline to each month in average daily pad usage [ Time Frame: Baseline, 4 weeks, 8 weeks, and 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in quality of life (QOL) [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
    QOL as measured by the American Urology Association Symptom Score (AUASS)
  • Change from baseline in quality of life (QOL) [ Time Frame: Bsaeleine and 12 weeks ] [ Designated as safety issue: No ]
    QOL as measured by the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)
  • Change from baseline to end of study on work productivity [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]
    Work productivity will be measured by the Work Productivity and Activity Impairment Questionnaire (WPAI)
  • Time from baseline to first day of returning to work [ Time Frame: Baseline and up to 12 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy
A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multicenter Study to Assess Efficacy and Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy

The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment of solifenacin succinate versus placebo in participants who are incontinent after Robotic Assisted Radical Prostatectomy.

This study will also assess the effect of 12 weeks of treatment with solifenacin succinate versus placebo on quality of life (QOL) as measured by questionnaires.

The study duration includes a 14-day treatment free wash-out period. The maximum total study duration is 15 weeks (2-3 week screening/washout period and a 12 week treatment period). The Baseline, Week 4, and Week 8 visits will be telephone contact visits.

Participants will complete an electronic daily pad use diary during the study duration. Participants will also be asked to complete several questionnaires during the study.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Urinary Incontinence
  • Drug: solifenacin succinate
    oral
    Other Names:
    • Vesicare
    • YM905
  • Drug: Placebo
    oral
  • Experimental: Solifenacin succinate
    Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily.
    Intervention: Drug: solifenacin succinate
  • Placebo Comparator: Placebo
    Participants received matching placebo tablets once a day for 12 weeks.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
640
October 2013
October 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ambulatory
  • Willing and able to complete the daily pad use diary, American Urology Association Symptom Score (AUASS) with Bother Score, the International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF), and the Work Productivity and Activity Impairment Questionnaire (WPAI)
  • Has not used any medication for over-active bladder symptoms for at least 14 days prior to enrollment
  • Diagnosed with prostate cancer, treated by Robotic Assisted Radical Prostatectomy, is voiding spontaneously and has urinary incontinence one week after removal of the indwelling catheter which requires management with 2 to 10 pads inclusive per day (24 hour days) for 7 consecutive days

Exclusion Criteria:

  • Evidence of severe neurologic damage post-prostatectomy
  • Evidence of chronic urologic inflammation such as interstitial cystitis and bladder stone; uncontrolled narrow angle glaucoma; urinary or gastric retention or neurogenic bladder
  • Symptomatic for urinary tract infection or has a urine culture result which requires treatment as determined by the investigator.
  • Clinically significant history of hepatic or renal impairment (2 X Upper Limit of Normal (ULN) values in alanine aminotransferase (ALT), aspartate aminotransferase (AST) or creatinine clearance < 30 ml/min)
  • History of diagnosed gastrointestinal obstruction disease
  • Any prior history of local radiation therapy to the prostate or rectum or any prior hormonal therapy or has planned such therapy during study conduct
  • Known or suspected hypersensitivity to solifenacin succinate, any components, or other anticholinergics
  • Treated with any investigational drug within last 30 days
  • History of a clinically significant illness or medical condition that would preclude participation in the study
  • Diagnosed with New York Heart Association Class III and IV heart failure
  • Any of the following peri-operative laboratory results: ALT > 2.0 ULN, AST > 2.0 ULN, serum creatinine > 1.5 mg/L, blood glucose > 130 mg/dL, blood urea nitrogen (BUN) > 23 mg/dL.
  • Severe hypertension on peri-operative evaluation which is defined as a sitting systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 110 mmHg, and which is not corrected
  • Electrolytes (sodium, potassium, chloride or bicarbonate) that are not in normal range and clinically significant as determined by the investigator in the perioperative period. Can be eligible if electrolytes are corrected to within normal range prior to randomization
  • Participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half lives, whichever is longer, prior to the initiation of Screening.
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT01371994
905-UC-050
No
Astellas Pharma Inc
Astellas Pharma Inc
Not Provided
Study Director: Medical Director Astellas Pharma Global Development
Astellas Pharma Inc
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP